These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice. Nguyen DH; Chen NG; Zhang Q; Le HT; Aguilar RJ; Yu YA; Cappello J; Szalay AA Mol Ther; 2013 Nov; 21(11):2054-62. PubMed ID: 23765443 [TBL] [Abstract][Full Text] [Related]
46. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Mansfield DC; Kyula JN; Rosenfelder N; Chao-Chu J; Kramer-Marek G; Khan AA; Roulstone V; McLaughlin M; Melcher AA; Vile RG; Pandha HS; Khoo V; Harrington KJ Gene Ther; 2016 Apr; 23(4):357-68. PubMed ID: 26814609 [TBL] [Abstract][Full Text] [Related]
47. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938 [TBL] [Abstract][Full Text] [Related]
48. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy. Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404 [TBL] [Abstract][Full Text] [Related]
49. Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines. Berchtold S; Beil J; Raff C; Smirnow I; Schell M; D'Alvise J; Gross S; Lauer UM Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076270 [TBL] [Abstract][Full Text] [Related]
50. Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. Wang H; Chen NG; Minev BR; Szalay AA J Transl Med; 2012 Aug; 10():167. PubMed ID: 22901246 [TBL] [Abstract][Full Text] [Related]
51. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer. Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344 [TBL] [Abstract][Full Text] [Related]
52. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Gentschev I; Patil SS; Adelfinger M; Weibel S; Geissinger U; Frentzen A; Chen NG; Yu YA; Zhang Q; Ogilvie G; Szalay AA Bioengineered; 2013; 4(2):84-9. PubMed ID: 23093804 [TBL] [Abstract][Full Text] [Related]
53. Oncolytic vaccinia virus acts synergistically with anti-PD-L1 antibody to enhance the killing of colon cancer cells by CD8 Wu R; Tong S; Yin J; Zhu Z; Mao Z; Xu L Pathol Res Pract; 2023 Jul; 247():154535. PubMed ID: 37257241 [TBL] [Abstract][Full Text] [Related]
56. Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps. Kober C; Rohn S; Weibel S; Geissinger U; Chen NG; Szalay AA J Transl Med; 2015 Jul; 13():216. PubMed ID: 26149494 [TBL] [Abstract][Full Text] [Related]
57. [Development of the drug oncolytic immunotherapy based on vaccinia viruses (Vaccinia virus, Orthopoxvirus, Chordopoxvirinae, Poxviridae) against breast cancer.]. Bauer TV; Tregubchak TV; Maksyutov AZ; Kolosova IV; Maksyutov RA; Gavrilova EV Vopr Virusol; 2020; 65(1):49-56. PubMed ID: 32496721 [TBL] [Abstract][Full Text] [Related]
58. Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination. Byrd D; Shepherd N; Lan J; Hu N; Amet T; Yang K; Desai M; Yu Q J Virol; 2014 Jun; 88(12):6819-31. PubMed ID: 24696488 [TBL] [Abstract][Full Text] [Related]
59. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113 [TBL] [Abstract][Full Text] [Related]
60. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Rojas JJ; Sampath P; Hou W; Thorne SH Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]